Factor IX Purification via Immunoaffinity Chromatography
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for purifying gamma carboxylated forms of proteins, such as Factor IX, face challenges in separating species with varying levels of gamma carboxylation, leading to suboptimal activity levels in recombinant production, particularly in CHO cells, where only about 50% specific activity is achieved due to incomplete gamma-carboxylation of the GLA domain.
Innovation Solution
The use of immunoaffinity chromatography with a coupled antibody specific to gamma-carboxyglutamic acid residues allows for the separation and purification of Factor IX species based on their gamma-carboxylation content, increasing the proportion of fully active forms and reducing inactive forms by overloading the chromatography material, thereby enhancing the specific activity of the purified Factor IX.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Manufacturing precision
If conventional purification methods are used for Factor IX, then the purification process is simple, but the specific activity is suboptimal (only about 50%) due to incomplete separation of gamma-carboxylated species
Solution Approach 1:
The patent introduces an immunoaffinity chromatography material as an intermediary substance that specifically binds to gamma-carboxylated Factor IX species. This mediator enables selective separation of different gamma-carboxylated forms (such as #1-11-Gla and #1-12-Gla) from the crude mixture, thereby achieving high specific activity purification that conventional methods cannot accomplish.
Solution Approach 2:
The patent changes the binding parameters of the chromatography material by using antibodies with specific affinity for gamma-carboxyglutamic acid residues. By adjusting the immunoglobulin G concentration (0.5-5 mg/mL) and binding conditions, the method optimizes the separation efficiency to enrich fully gamma-carboxylated Factor IX species while removing partially carboxylated forms.
2Manufacturing precision
If immunoaffinity chromatography is used to separate gamma-carboxylated species, then the specific activity increases, but the device complexity and process complexity increase
Solution Approach 1:
The patent extracts and isolates the fully gamma-carboxylated Factor IX species (#1-12-Gla and #1-11-Gla) from the complex mixture of partially carboxylated species through immunoaffinity chromatography. This extraction process removes the harmful or less active components (such as #1-10-Gla and other partially carboxylated forms) while concentrating the desired high-activity species, thereby achieving purification with enhanced specific activity.
3Reliability
If conventional purification is used, then the process is straightforward, but the proportion of inactive Factor IX species remains high
Solution Approach 1:
The patent replaces conventional mechanical or chemical purification methods with immunoaffinity chromatography, which uses specific antibody-antigen recognition mechanisms. This substitution enables selective binding and separation based on the gamma-carboxylation status of Factor IX species, achieving high reliability in terms of activity level by enriching fully carboxylated forms while maintaining a relatively streamlined process through standardized chromatography protocols.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This method effectively increases the specific activity of Factor IX by selectively enriching for higher gamma-carboxylated species, such as #1-11- and #1-12-Gla forms, while decreasing the levels of less active species like #1-10-Gla, resulting in a more active and pure Factor IX formulation.
Implementation Method 1
The use of immunoaffinity chromatography with a coupled antibody specific to gamma-carboxyglutamic acid residues allows for the separation and purification of Factor IX species based on their gamma-carboxylation content
Data Source
AI summary
The present invention relates to the purification of vitamin K-dependent blood coagulation factors, such as Factor IX (FIX). In particular, the invention provides a method for purifying Factor IX having a desired content of gamma-carboxyglutamic acid from a sample comprising a mixture of species of said Factor IX having different contents of gamma-carboxyglutamic acid, said method comprising the steps of: (a) loading said Factor IX sample onto an immunoaffinity chromatography material coupled to a binding moiety for gamma-carboxyglutamic acid; (b) eluting said Factor IX; and (c) selecting a fraction obtained from said elution wherein the polypeptides in the fraction have the desired content of gamma-carboxyglutamic acids; characterized in that the total concentration of Factor IX within said sample exceeds the binding ability of the immunoaffinity chromatography material.